WO2012087040A3 - 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법 - Google Patents

광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법 Download PDF

Info

Publication number
WO2012087040A3
WO2012087040A3 PCT/KR2011/009967 KR2011009967W WO2012087040A3 WO 2012087040 A3 WO2012087040 A3 WO 2012087040A3 KR 2011009967 W KR2011009967 W KR 2011009967W WO 2012087040 A3 WO2012087040 A3 WO 2012087040A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
therapy
acetylated
polysaccharide
photodynamic diagnosis
Prior art date
Application number
PCT/KR2011/009967
Other languages
English (en)
French (fr)
Other versions
WO2012087040A2 (ko
Inventor
나건
이방원
배병찬
Original Assignee
(주)파낙스이엠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)파낙스이엠 filed Critical (주)파낙스이엠
Priority to JP2013543111A priority Critical patent/JP5721853B2/ja
Priority to RU2013119911/15A priority patent/RU2537228C1/ru
Priority to EP11851627.7A priority patent/EP2656847A4/en
Priority to US13/877,162 priority patent/US8946394B2/en
Priority to KR1020137021979A priority patent/KR101847187B1/ko
Priority to CN201180051894.1A priority patent/CN103260626B/zh
Publication of WO2012087040A2 publication Critical patent/WO2012087040A2/ko
Publication of WO2012087040A3 publication Critical patent/WO2012087040A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본 발명은 광역학 진단 또는 치료를 위한 아세틸화 생체 적합성 다당류와 프탈로시아닌 화합물의 결합체 및 이의 제조방법에 관한 것으로서, 보다 구체적으로는 생체 적합성 다당류를 아세틸화시키고 아세틸화된 다당류에 프탈로시아닌 화합물을 결합시킨 광역학 진단 또는 치료용 결합체 및 이의 제조방법에 관한 것이다. 본 발명에 따른 상기 광역학 진단 또는 치료용 결합체는 다당류를 아세틸화시킴으로써 용매에서의 용해도를 높여 여러 가지 화학적 개질이 가능하며, 암세포만을 특이적으로 표적할 수 있고 암세포에 대한 선택성과 축적성이 우수할 뿐만 아니라 근적외선 조사시 암세포를 사멸하는 효과가 우수하고 반면 암세포 이외의 세포에 대해서는 근적외선 조사시에도 세포독성을 나타내지 않아 체내 안정성이 우수한 효과가 있으므로 광역학을 이용한 질병의 진단 또는 치료에 유용하게 사용할 수 있는 특징이 있다.
PCT/KR2011/009967 2010-12-21 2011-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법 WO2012087040A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2013543111A JP5721853B2 (ja) 2010-12-21 2011-12-21 光力学診断または治療のための結合体およびその製造方法
RU2013119911/15A RU2537228C1 (ru) 2010-12-21 2011-12-21 Конъюгат для фотодинамической диагностики или терапии, а также способ его получения
EP11851627.7A EP2656847A4 (en) 2010-12-21 2011-12-21 CONJUGATE FOR PHOTODYNAMIC DIAGNOSIS OR THERAPY AND PREPARATION METHOD THEREOF
US13/877,162 US8946394B2 (en) 2010-12-21 2011-12-21 Conjugate for photodynamic diagnosis or therapy and method for preparing same
KR1020137021979A KR101847187B1 (ko) 2010-12-21 2011-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
CN201180051894.1A CN103260626B (zh) 2010-12-21 2011-12-21 用于光动力学诊断或治疗的轭合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KRPCT/KR2010/009173 2010-12-21
PCT/KR2010/009173 WO2012086857A1 (ko) 2010-12-21 2010-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법

Publications (2)

Publication Number Publication Date
WO2012087040A2 WO2012087040A2 (ko) 2012-06-28
WO2012087040A3 true WO2012087040A3 (ko) 2012-10-04

Family

ID=46314113

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2010/009173 WO2012086857A1 (ko) 2010-12-21 2010-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
PCT/KR2011/009967 WO2012087040A2 (ko) 2010-12-21 2011-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/009173 WO2012086857A1 (ko) 2010-12-21 2010-12-21 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법

Country Status (7)

Country Link
US (1) US8946394B2 (ko)
EP (1) EP2656847A4 (ko)
JP (1) JP5721853B2 (ko)
KR (1) KR101847187B1 (ko)
CN (1) CN103260626B (ko)
RU (1) RU2537228C1 (ko)
WO (2) WO2012086857A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765220B2 (en) 2013-08-22 2017-09-19 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
CN104069492B (zh) * 2014-01-24 2019-05-28 中国科学院福建物质结构研究所 靶向表达尿激酶受体的肿瘤的光敏剂及其制备方法和用途
CN105412924B (zh) * 2014-08-22 2018-10-16 苏州大学 具有血液稳定性及靶向性的含糖光动力学疗法纳米粒子及其制备方法
KR101781598B1 (ko) * 2014-09-25 2017-09-25 한양대학교 산학협력단 광역학 치료용 테트라피라지노폴피라진 유도체 및 이의 제조방법
CA3231845A1 (en) 2016-04-01 2017-10-05 Sony Group Corporation Ultra bright dimeric or polymeric fluorescent and colored dyes
AU2017264861B2 (en) 2016-05-11 2021-09-23 Sony Group Corporation Ultra bright dimeric or polymeric dyes
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
KR102081666B1 (ko) * 2017-04-07 2020-02-27 서울대학교산학협력단 암 치료용 약학 조성물
EP3691689A1 (en) * 2017-10-05 2020-08-12 Sony Corporation Programmable dendritic drugs
WO2019099789A1 (en) 2017-11-16 2019-05-23 Sony Corporation Programmable polymeric drugs
EP3769085B1 (en) 2018-03-19 2022-08-24 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
EP3801643A4 (en) 2018-05-09 2022-04-20 Virginia Commonwealth University SMALL NEAR-IR ACTIVABLE FLUORESCENT MOLECULES WITH A DUAL MODE OF CYTOTOXICITY
JP2021529194A (ja) 2018-06-27 2021-10-28 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
WO2020189641A1 (ja) * 2019-03-18 2020-09-24 株式会社日本触媒 フタロシアニン化合物ならびにこれを用いるリポソーム製剤および癌／腫瘍治療剤
US20220218834A1 (en) * 2019-05-20 2022-07-14 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
JP7239904B2 (ja) 2019-09-26 2023-03-15 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
CN111529715B (zh) * 2020-04-22 2021-10-01 山东大学 一种右旋糖酐-二十二碳六烯酸偶联聚合物及其合成方法和应用
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114409663B (zh) * 2022-01-28 2023-05-30 福州大学 靶向Mcl-1酶的锌酞菁3-氯-6甲基苯并[b]噻吩-2-羧酸轭合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030046394A (ko) * 2000-07-27 2003-06-12 포토큐레 에이에스에이 조성물
WO2005110388A1 (en) * 2004-05-10 2005-11-24 Hofmann Robert F Use of targeted oxidative therapeutic formulation in treatment of cancer
US7153841B2 (en) * 2001-03-21 2006-12-26 L. Molteni & C. Dei Fratelli Alitti Societa Di Esercizio S.P.A. Metal substituted non-centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
JP2004262777A (ja) * 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
CN101234203B (zh) * 2007-01-30 2012-07-18 中国科学院福建物质结构研究所 用于抗肿瘤治疗的医用光敏剂及其制备方法
IN2012DN02780A (ko) 2009-10-06 2015-09-18 Immunogen Inc

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030046394A (ko) * 2000-07-27 2003-06-12 포토큐레 에이에스에이 조성물
US7153841B2 (en) * 2001-03-21 2006-12-26 L. Molteni & C. Dei Fratelli Alitti Societa Di Esercizio S.P.A. Metal substituted non-centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
WO2005110388A1 (en) * 2004-05-10 2005-11-24 Hofmann Robert F Use of targeted oxidative therapeutic formulation in treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANGYUAN LI ET AL.: "Acetylated hyaluronic acid/photosensitizer conjugate for the preparation of nanogels with controllable phototoxicity: synthesis, characterization, autophotoquenching properties, and in vitro phototoxicity against HeLa cells", BIOCONJUGATE CHEM., vol. 21, no. 7, 21 July 2010 (2010-07-21), pages 1312 - 1320, XP055116199 *
See also references of EP2656847A4 *

Also Published As

Publication number Publication date
WO2012086857A1 (ko) 2012-06-28
CN103260626B (zh) 2015-04-01
RU2537228C1 (ru) 2014-12-27
US8946394B2 (en) 2015-02-03
KR101847187B1 (ko) 2018-04-10
KR20140027096A (ko) 2014-03-06
CN103260626A (zh) 2013-08-21
JP2014500273A (ja) 2014-01-09
US20130281679A1 (en) 2013-10-24
RU2013119911A (ru) 2014-12-10
EP2656847A2 (en) 2013-10-30
EP2656847A4 (en) 2016-06-29
WO2012087040A2 (ko) 2012-06-28
JP5721853B2 (ja) 2015-05-20

Similar Documents

Publication Publication Date Title
WO2012087040A3 (ko) 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
WO2010009111A3 (en) A drug depot implantable within a synovial joint
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
WO2012054742A3 (en) Implantable polymer for bone and vascular lesions
IN2014DN08886A (ko)
WO2011034627A3 (en) Methods and apparatus for introducing cells at a tissue site
WO2012158952A8 (en) Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells and hydrogel
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
WO2012002760A3 (ko) 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
EA201170040A1 (ru) Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
WO2013012628A3 (en) Immune-stimulating photoactive hybrid nanoparticles
WO2010065902A3 (en) Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2008109832A3 (en) Viable near-infrared fluorochrome labeled cells and methods of making and using same
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2010048144A3 (en) Imaging and radiotherapy methods
WO2010151074A3 (ko) 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물
WO2006081445A3 (en) Treatment of metastasized tumors
WO2009045535A3 (en) Fluorine-18 derivative of dasatinib and uses thereof
WO2010080720A3 (en) Conjugates of a lysosomal enzyme moiety and a water soluble polymer
WO2010022201A3 (en) Folinic acid derivatives for promoting bone growth
NZ610853A (en) Phenylketone carboxylate compounds and pharmaceutical uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11851627

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011851627

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013543111

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013119911

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13877162

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137021979

Country of ref document: KR

Kind code of ref document: A